← SS Innovations International Inc. Common Stock overview

SS Innovations International Inc. Common Stock vs Globus Medical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

SS Innovations International Inc. Common Stock (SSII)

Q3 2026
▲3

SSII's surgical robot adoption accelerates; losses and financing remain the drag

  • Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.

    This is the core demand engine behind SSII's growth story this period.

  • Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.

    It shows the financial results that validate the adoption trend.

  • New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.

    Geographic and clinical expansion is a fresh driver of future sales.

  • Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.

    It is the main counterweight investors must weigh against the growth story.

August 2026
▲3

SSII's surgical robot adoption accelerates; losses and financing remain the drag

  • Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.

    This is the core demand engine behind SSII's growth story this period.

  • Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.

    It shows the financial results that validate the adoption trend.

  • New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.

    Geographic and clinical expansion is a fresh driver of future sales.

  • Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.

    It is the main counterweight investors must weigh against the growth story.

Latest
▲3

SSII's surgical robot adoption accelerates; losses and financing remain the drag

  • Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.

    This is the core demand engine behind SSII's growth story this period.

  • Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.

    It shows the financial results that validate the adoption trend.

  • New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.

    Geographic and clinical expansion is a fresh driver of future sales.

  • Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.

    It is the main counterweight investors must weigh against the growth story.

Globus Medical (GMED)

Q3 2026
▲3▼1

Globus Medical beats Q2, buys AI health firm, wins EU clearance for imaging robot

  • Q2 beat and raised guidance Globus Medical reported Q2 revenue of $789.6 million, up 5.9% and above estimates, and beat profit expectations while raising full-year guidance. US Spine rose 7% and international spine 14%, showing the core business is still taking market share.

    The latest earnings beat and guidance raise are the clearest new evidence of business strength.

  • AI digital health acquisition Globus Medical bought Higgs Boson Health, a Duke-incubated AI software company, to build 'surgical intelligence' that tracks patient outcomes across the whole episode of care. It adds technology and talent rather than near-term sales, so it supports the long-term growth story more than this quarter's numbers.

    A new acquisition expands Globus Medical's technology and talent, a fresh strategic driver.

  • EU approval for Excelsius3D imaging system Globus Medical's Excelsius3D imaging system received CE marking, letting it be sold in the EU and UK. The system combines 3D CT, 2D fluoroscopy and digital X-ray and works with its ExcelsiusGPS surgical robot, so it can lift sales of the whole robotic ecosystem abroad.

    New regulatory clearance opens European commercialization, a concrete new growth avenue.

  • Insurance worries and governance probe Intuitive Surgical warned that insurance plan changes could slow US procedure growth, dragging medical device stocks including Globus Medical down 4.4%. Separately, Kuehn Law is investigating whether Globus Medical officers and directors breached their duties through possible self-dealing, a governance cloud that can weigh on sentiment.

    These are the main new negatives: a sector demand scare and a legal/governance investigation.

August 2026
▲3▼1

Globus Medical beats Q2, buys AI health firm, wins EU clearance for imaging robot

  • Q2 beat and raised guidance Globus Medical reported Q2 revenue of $789.6 million, up 5.9% and above estimates, and beat profit expectations while raising full-year guidance. US Spine rose 7% and international spine 14%, showing the core business is still taking market share.

    The latest earnings beat and guidance raise are the clearest new evidence of business strength.

  • AI digital health acquisition Globus Medical bought Higgs Boson Health, a Duke-incubated AI software company, to build 'surgical intelligence' that tracks patient outcomes across the whole episode of care. It adds technology and talent rather than near-term sales, so it supports the long-term growth story more than this quarter's numbers.

    A new acquisition expands Globus Medical's technology and talent, a fresh strategic driver.

  • EU approval for Excelsius3D imaging system Globus Medical's Excelsius3D imaging system received CE marking, letting it be sold in the EU and UK. The system combines 3D CT, 2D fluoroscopy and digital X-ray and works with its ExcelsiusGPS surgical robot, so it can lift sales of the whole robotic ecosystem abroad.

    New regulatory clearance opens European commercialization, a concrete new growth avenue.

  • Insurance worries and governance probe Intuitive Surgical warned that insurance plan changes could slow US procedure growth, dragging medical device stocks including Globus Medical down 4.4%. Separately, Kuehn Law is investigating whether Globus Medical officers and directors breached their duties through possible self-dealing, a governance cloud that can weigh on sentiment.

    These are the main new negatives: a sector demand scare and a legal/governance investigation.

Latest
▲3▼1

Globus Medical beats Q2, buys AI health firm, wins EU clearance for imaging robot

  • Q2 beat and raised guidance Globus Medical reported Q2 revenue of $789.6 million, up 5.9% and above estimates, and beat profit expectations while raising full-year guidance. US Spine rose 7% and international spine 14%, showing the core business is still taking market share.

    The latest earnings beat and guidance raise are the clearest new evidence of business strength.

  • AI digital health acquisition Globus Medical bought Higgs Boson Health, a Duke-incubated AI software company, to build 'surgical intelligence' that tracks patient outcomes across the whole episode of care. It adds technology and talent rather than near-term sales, so it supports the long-term growth story more than this quarter's numbers.

    A new acquisition expands Globus Medical's technology and talent, a fresh strategic driver.

  • EU approval for Excelsius3D imaging system Globus Medical's Excelsius3D imaging system received CE marking, letting it be sold in the EU and UK. The system combines 3D CT, 2D fluoroscopy and digital X-ray and works with its ExcelsiusGPS surgical robot, so it can lift sales of the whole robotic ecosystem abroad.

    New regulatory clearance opens European commercialization, a concrete new growth avenue.

  • Insurance worries and governance probe Intuitive Surgical warned that insurance plan changes could slow US procedure growth, dragging medical device stocks including Globus Medical down 4.4%. Separately, Kuehn Law is investigating whether Globus Medical officers and directors breached their duties through possible self-dealing, a governance cloud that can weigh on sentiment.

    These are the main new negatives: a sector demand scare and a legal/governance investigation.